How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

21,268 results for

Hematology and Oncology Links

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Hematology and Oncology Links

Hematology and Oncology Links Hematology and Oncology Links Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Hematology and Oncology (...) Links Hematology and Oncology Links Aka: Hematology and Oncology Links II. Resources: Oncology NCI Adult Cancer Treatment National Cancer Institute (NCI) Cancer.gov Clinical Trial Search OncoLink at University of Pennsylvania Cancer Center Oncology Online Cancer Treatment Prediction Tools Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Hematology and Oncology Links." Click on the image (or right click) to open the source website

2018 FP Notebook

2. Treatment of Clostridium Difficile in Colonized Patients in the Hematology Oncology Population

Treatment of Clostridium Difficile in Colonized Patients in the Hematology Oncology Population Treatment of Clostridium Difficile in Colonized Patients in the Hematology Oncology Population - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Treatment of Clostridium Difficile in Colonized Patients in the Hematology Oncology Population The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03030248 Recruitment Status : Not yet

2017 Clinical Trials

3. Critical Care Outcomes of Hematologic Oncology Patients

Critical Care Outcomes of Hematologic Oncology Patients Critical Care Outcomes of Hematologic Oncology Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Critical Care Outcomes of Hematologic Oncology (...) With Hematologic Malignancy and Hematopoietic Cell Transplantation Actual Study Start Date : February 26, 2018 Estimated Primary Completion Date : May 20, 2020 Estimated Study Completion Date : December 20, 2020 Resource links provided by the National Library of Medicine related topics: Groups and Cohorts Go to Outcome Measures Go to Primary Outcome Measures : 1 year survival [ Time Frame: 1 year ] 1 year survival in enrolled patients Secondary Outcome Measures : Intensive Care Unit survival [ Time Frame: 1

2017 Clinical Trials

4. Implementation of a Return Home With a Hospitalization at Home or With a Home Health Care Provider From the Services of Oncopneumology, Oncology and Hematology of University Hospital of Strasbourg

at Home or With a Home Health Care Provider From the Services of Oncopneumology, Oncology and Hematology of University Hospital of Strasbourg: Observational, Prospective, Monocentric, Non-interventional Study. Advantages, Disadvantages, Limitations Actual Study Start Date : July 12, 2017 Estimated Primary Completion Date : July 2018 Estimated Study Completion Date : July 2018 Resource links provided by the National Library of Medicine related topics: Groups and Cohorts Go to Outcome Measures Go (...) Implementation of a Return Home With a Hospitalization at Home or With a Home Health Care Provider From the Services of Oncopneumology, Oncology and Hematology of University Hospital of Strasbourg Implementation of a Return Home With a Hospitalization at Home or With a Home Health Care Provider From the Services of Oncopneumology, Oncology and Hematology of University Hospital of Strasbourg - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer

2017 Clinical Trials

5. New Oncologic Therapies Mean New Oncologic Emergencies: An Approach to Immunotherapy-Related Adverse Events

of pneumonitis and dermatologic complications. Information on the diagnosis and management of hepatic, endocrine, hematological, cardiac and rheumatoid complications, which are less common, can be found through Cancer Care Ontario. 5 Other resources include the American Society of Clinical Oncology 2 and European Society of Medical Oncology Clinical Practice Guidelines. 3 Treatment of irAEs outside of acute management in the ED is beyond the scope of this article. Emergency physicians should have a high (...) of unwell patients - A link to our provincial toolkit: https://www.cancercareontario.ca/en/guidelines-advice/modality/immunotherapy/immune-therapy-toolkit Ultimately, the importance of involving the oncology team as early as possible in the work-up and treatment of suspected or proven immune-related adverse events cannot be overstated. This is particularly important for patients enrolled in clinical trials involving immune checkpoint inhibitors. Dr. Lacey D. Pitre FRCP(C) Northeast Cancer Centre

2018 CandiEM

6. “Hard” Drug Repurposing for Precision Oncology: The Missing Link? (PubMed)

“Hard” Drug Repurposing for Precision Oncology: The Missing Link? 29962954 2018 11 14 1663-9812 9 2018 Frontiers in pharmacology Front Pharmacol "Hard" Drug Repurposing for Precision Oncology: The Missing Link? 637 10.3389/fphar.2018.00637 Pantziarka Pan P Anticancer Fund, Brussels, Belgium. The George Pantziarka TP53 Trust, London, United Kingdom. Bouche Gauthier G Anticancer Fund, Brussels, Belgium. André Nicolas N Department of Pediatric Hematology-Oncology, Assistance Publique Hôpitaux (...) de Marseille, La Timone Hospital, Marseille, France. Centre de Recherche en Oncologie Biologique et en Oncopharmacologie, Institut National de la Santé et de la Recherche Médicale-UMR 79 911, Aix-Marseille University, Marseille, France. Metronomics Global Health Initiative, Marseille, France. eng Journal Article 2018 06 14 Switzerland Front Pharmacol 101548923 1663-9812 drug Repositioning drug development strategy drug repurposing precision oncology targeted therapy 2018 04 17 2018 05 29 2018 7 3

Full Text available with Trip Pro

2018 Frontiers in pharmacology

7. Hematology and Oncology Books

Books Hematology and Oncology Books Aka: Hematology and Oncology Books , Hematology and Oncology Resources II. Resources: Medical Library Recommendations Carr (2012) Clinical Hematology Atlas, Saunders Devita (2014) Cancer: Principles, Lippincott III. Resources: Patient Library Recommendations Siegel (1990) Love, Medicine and Miracles Remen (2001) My Grandfather's Blessing, Riverhead Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term (...) Hematology and Oncology Books Hematology and Oncology Books Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Hematology and Oncology

2018 FP Notebook

8. Initial diagnostic workup of acute leukemia: guideline from the College of American Pathologists and the American Society of Hematology.

Diagnosis Evaluation Hematology Oncology Pathology Clinical Laboratory Personnel Physician Assistants Physicians To recommend laboratory testing for the initial workup for proper diagnosis, determination of prognostic factors, and possible future monitoring of acute leukemias (ALs), including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and ALs of ambiguous lineage, in children and adults To answer the following key questions: What clinical and laboratory information should (...) Lake City; Joan Etzell, MD, Sutter Health Shared Laboratory, Livermore, California; Kathryn Foucar, MD, Department of Pathology, University of New Mexico, Albuquerque; Robert P. Hasserjian, MD, Department of Pathology, Massachusetts General Hospital, Boston; J. Douglas Rizzo, MD, Department of Hematology and Oncology, Medical College of Wisconsin, Milwaukee; Karl Theil, MD, Department of Clinical Pathology, Cleveland Clinic, Cleveland, Ohio; Sa A. Wang, MD, Department of Hematopathology, MD

2017 National Guideline Clearinghouse (partial archive)

9. Bone Marrow Synoptic Reporting for Hematologic Neoplasms

City (Dr Perkins); the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (Dr Reichard); Utah Pathology Services, Inc, Salt Lake City (Dr Taylor); the Department of Hematology/Medical Oncology, Newland Medical Associates, Novi, Michigan (Dr Terebelo); the Departments of Governance (Ms Colasacco) and Surveys (Ms Thomas), College of American Pathologists, Northfield, Illinois; and the Quality and Guidelines Department, American Society of Clinical Oncology, Alexandria (...) Bone Marrow Synoptic Reporting for Hematologic Neoplasms Bone Marrow Synoptic Reporting for Hematologic Neoplasms: Guideline From the College of American Pathologists Pathology and Laboratory Quality Center | Archives of Pathology & Laboratory Medicine | | > > > Bone Marrow Synoptic Reporting for Hematologic Neoplasms: Guideline Fr... Volume 140, Issue 9 (September 2016) Alerts for the Journal Click to get an email alert for every new issue of Archives of Pathology & Laboratory Medicine X Email

Full Text available with Trip Pro

2016 College of American Pathologists

10. Next generation sequencing gene panels for targeted therapy in oncology and haemato-oncology

Next generation sequencing gene panels for targeted therapy in oncology and haemato-oncology 2015 www.kce.fgov.be KCE REPORT 240Cs SYNTHESIS NEXT GENERATION SEQUENCING GENE PANELS FOR TARGETED THERAPY IN ONCOLOGY AND HAEMATO- ONCOLOGY 2015 www.kce.fgov.be KCE REPORT 240Cs HEALTH TECHNOLOGY ASSESSMENT SYNTHESIS NEXT GENERATION SEQUENCING GENE PANELS FOR TARGETED THERAPY IN ONCOLOGY AND HAEMATO- ONCOLOGY MARC VAN DEN BULCKE, LORENA SAN MIGUEL, ROBERTO SALGADO, ELS DE QUECKER, HARLINDE DE SCHUTTER (...) , ANOUK WAEYTENS, PETER VAN DEN BERGHE, SABINE TEJPAR, JEROEN VAN HOUDT, STEVEN VAN LAERE, BRIGITTE MAES, FRANK HULSTAERT KCE Report 240Cs NGS panel tests for Targeted Treatment 1 ¦ FOREWORD Personalized Medicine has been announced already years ago as an important breakthrough in oncology. After determining the genetic fingerprint of the tumour a highly targeted medicine is administered, highly efficacious and with very few side-effects. At least this is our hope. In reality this theoretical

2015 Belgian Health Care Knowledge Centre

11. Hematology and Oncology Links

Hematology and Oncology Links Hematology and Oncology Links Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Hematology and Oncology (...) Links Hematology and Oncology Links Aka: Hematology and Oncology Links II. Resources: Oncology NCI Adult Cancer Treatment National Cancer Institute (NCI) Cancer.gov Clinical Trial Search OncoLink at University of Pennsylvania Cancer Center Oncology Online Cancer Treatment Prediction Tools Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Hematology and Oncology Links." Click on the image (or right click) to open the source website

2015 FP Notebook

12. Cohort Study of German Hematological / Oncological Wards to Assess the Effect of Contact Precautions on Nosocomial Colonization With Vancomycin Resistant Enterococci

Cohort Study of German Hematological / Oncological Wards to Assess the Effect of Contact Precautions on Nosocomial Colonization With Vancomycin Resistant Enterococci Cohort Study of German Hematological / Oncological Wards to Assess the Effect of Contact Precautions on Nosocomial Colonization With Vancomycin Resistant Enterococci - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x (...) × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Cohort Study of German Hematological / Oncological Wards to Assess the Effect of Contact Precautions on Nosocomial Colonization With Vancomycin Resistant Enterococci (CONTROL) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been

2015 Clinical Trials

13. Assessing the Effect of Contact Isolation on Nosocomial Colonization With ESBL-EC in German Hematology/Oncology Wards

: 2264 participants Observational Model: Cohort Time Perspective: Prospective Official Title: A Hospital-based Cohort Study in German Hematological / Oncological Wards to Assess the Effect of Contact Isolation on Nosocomial Colonization With ESBL-producing Escherichia Coli (CONTAIN Study) Study Start Date : January 2015 Estimated Primary Completion Date : June 2016 Estimated Study Completion Date : June 2016 Resource links provided by the National Library of Medicine related topics: Groups (...) Assessing the Effect of Contact Isolation on Nosocomial Colonization With ESBL-EC in German Hematology/Oncology Wards Assessing the Effect of Contact Isolation on Nosocomial Colonization With ESBL-EC in German Hematology/Oncology Wards - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2015 Clinical Trials

14. Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders

: Interventional (Clinical Trial) Actual Enrollment : 20 participants Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Implementation of Rapid Infusion Rituximab in a Pilot Group of Adolescents With Hematologic, Oncologic, and Rheumatologic Disorders Study Start Date : June 2015 Actual Primary Completion Date : January 2017 Actual Study Completion Date : January 2017 Resource links provided by the National Library (...) Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2015 Clinical Trials

15. Integration of Palliative Care Into Standard Oncology Care

Integration of Palliative Care Into Standard Oncology Care Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2016.70.1474 Journal of Clinical Oncology - published online before print October 31, 2016 PMID: Integration (...) of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update x Betty R. Ferrell , x Jennifer S. Temel , x Sarah Temin , x Erin R. Alesi , x Tracy A. Balboni , x Ethan M. Basch , x Janice I. Firn , x Judith A. Paice , x Jeffrey M. Peppercorn , x Tanyanika Phillips , x Ellen L. Stovall , x Camilla Zimmermann , and x Thomas J. Smith Betty R. Ferrell, City of Hope Medical Center, Duarte, CA; Jennifer S. Temel and Jeffrey M. Peppercorn, Massachusetts

2016 American Society of Clinical Oncology Guidelines

16. A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies

escalation Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Phase I Study of YY-20394 Given Orally to Patients With Relapsed or Refractory B Cell Hematologic Malignancies Actual Study Start Date : December 25, 2017 Estimated Primary Completion Date : March 30, 2019 Estimated Study Completion Date : May 30, 2019 Resource links provided by the National Library of Medicine resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: YY-20394 YY-20394 is a selective (...) A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2018 Clinical Trials

17. Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

City of Hope ( Site 0001) Recruiting Duarte, California, United States, 91010 Contact: Study Coordinator 626-256-2405 Pacific Cancer Care ( Site 0006) Recruiting Monterey, California, United States, 93940 Contact: Study Coordinator 831-375-4105 UCLA Hematology/Oncology -Santa Monica ( Site 0007) Recruiting Santa Monica, California, United States, 90404 Contact: Study Coordinator 310-582-4067 United States, Texas Texas Oncology-Austin Midtown ( Site 8002) Recruiting Austin, Texas, United States (...) Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record

2018 Clinical Trials

18. Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults

Gesù Department of Pediatric Hematology and Oncology Piazza Sant'Onofrio, 4, 00165 Rome, Italy More Information Go to Layout table for additonal information Responsible Party: Menarini Group ClinicalTrials.gov Identifier: Other Study ID Numbers: FLO-02 2016-001445-61 ( EudraCT Number ) First Posted: July 30, 2018 Last Update Posted: July 30, 2018 Last Verified: June 2018 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product (...) Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2018 Clinical Trials

19. Study of Venetoclax With the mIDH1 Inhibitor Ivosidenib (AG120) in IDH1-Mutated Hematologic Malignancies

Hematologic Malignancies Actual Study Start Date : March 19, 2018 Estimated Primary Completion Date : September 2019 Estimated Study Completion Date : September 2019 Resource links provided by the National Library of Medicine related topics: available for: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Ivosidenib + Venetoclax Participants take Venetoclax by mouth 1 time each day on Days 1-14 of each 28 day cycle. Participants take Ivosidenib by mouth once each day (...) Study of Venetoclax With the mIDH1 Inhibitor Ivosidenib (AG120) in IDH1-Mutated Hematologic Malignancies Study of Venetoclax With the mIDH1 Inhibitor Ivosidenib (AG120) in IDH1-Mutated Hematologic Malignancies - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2018 Clinical Trials

20. Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies

: No Criteria Inclusion Criteria: 1.18- 75 years of age. 2.Histologically or cytologically confirmed diagnosis of relapsed or refractory indolent B-cell hematologic malignancies, including but not limited to CLL / SLL, FL (grade 1, 2 or 3a), or MZL. 3.Patients have received at least 1 prior regimen (at least 2 cycles). 4.Eastern Cooperative Oncology Group (ECOG) performance score of 0-2. 5.Life expectancy ≥ 3 months. 6.Patients have at least 1 measurable lesion that measures ≥1.5 cm in a single dimension (...) Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>